Reata Pharmaceuticals Revenue and Competitors

Dallas, TX USA

Location

$1.4B

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Reata Pharmaceuticals's estimated annual revenue is currently $53.6M per year.(i)
  • Reata Pharmaceuticals received $125.0M in venture funding in June 2018.
  • Reata Pharmaceuticals's estimated revenue per employee is $128,511
  • Reata Pharmaceuticals's total funding is $1.4B.

Employee Data

  • Reata Pharmaceuticals has 417 Employees.(i)
  • Reata Pharmaceuticals grew their employee count by 44% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$26.7M13320%N/AN/A
#2
$13.5M676%N/AN/A
#3
$62.5M0N/AN/AN/A
#4
$8.8M44-6%N/AN/A
#5
$58.3M2909%N/AN/A
#6
$21.3M1068%N/AN/A
#7
$78.6M3915%N/AN/A
#8
$12.3M6115%N/AN/A
#9
$6M303%N/AN/A
#10
$53.6M41744%$1.4BN/A
Add Company

Reata Pharmaceuticals, Inc. (Nasdaq:RETA) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata's two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$1.4B

Total Funding

417

Number of Employees

$53.6M

Revenue (est)

44%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Reata Pharmaceuticals News

2022-04-17 - Brokerages Set Reata Pharmaceuticals, Inc. (NASDAQ:RETA ...

Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) has earned an average rating of “Buy” from the eight research firms that are covering...

2022-03-30 - Reata Pharmaceuticals: Once Beaten, Twice Shy

Reata Pharmaceuticals (NASDAQ:RETA) stock didn't blink an eye after the FDA stuck it with a CRL because whatever damage was to be done had...

2022-03-30 - Reata Pharma down 31% as a consequence of FDA docs on ...

Reata Pharmaceuticals (RETA -31.4%) are struggling today, likely as a result of U.S. FDA briefing documents on Amylyx Pharma's (AMLX -55.3%)...

2021-11-08 - REATA PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT PROGRAMS - Form 8-K

REATA PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT PROGRAMS ADVISORY COMMITTEE MEETING for BARDOXOLONE FOR PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME scheduled FOR DECEMBER 8, 2021 SUBMITTED MAA TO THE EMA FOR BARDOXOLONE ...

2021-05-20 - REATA PHARMACEUTICALS, INC. Reata Pharmaceuticals : Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich's Ataxia

PLANO, Texas - Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ('Reata,' the 'Company,' or 'we'), a clinical-stage biopharmaceutical company, announced that it received a communication from the Division of Neurology Products 1 ('Division') of the U.S. Food and Drug Administration ('FDA') stating that ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$141.4M419-9%N/A
#2
$76.1M42046%N/A
#3
$76.1M42046%N/A
#4
$117.2M426N/AN/A
#5
$159.1M4391%N/A

Reata Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2003-09-17$5.2MLead Investor: OjaiArticle
2004-11-12$12.0MLead Investor: MultiArticle
2006-08-07$22.6MUndisclosedCardinal Investment CompanyArticle
2007-07-09$25.0MUndisclosedArticle
2009-03-27$32.0MUndisclosedArticle
2010-07-13$78.0MUndisclosedCPMG Inc, Novo A/SArticle
2016-12-07$UndisclosedUndisclosedCitigroupArticle
2017-04-04$35.0MUndisclosedOxford Finance LLCArticle
2017-07-28$115.9MUndisclosedMultipleArticle
2018-06-15$125.0MUndisclosedOxford Finance LLCArticle